Aferetica S.r.l. Alternatives & Competitors
7 companies similar to Aferetica S.r.l. — To Give More Chance to Life
Companies similar to Aferetica S.r.l.
Pennsylvania Biotechnology Center
One of the Nation’s Most Successful Life Sciences Incubators
Aurion Biotech
We're on a mission to cure blindness with our transformational platform of advanced therap...
DSI Renal
Leading the way in dialysis care with ambitious plans for expansion through strategic acqu...
Rival Readout
Competing with Aferetica S.r.l.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
ARTCLINE GmbH
Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe...
Ciel Medical
Innovative solutions for critical care and kidney stone treatment since 2012
PrecisemAb Biotech Co., Ltd.
We are committed to changing the world to be better by creating safer and disease-directed...
About Aferetica S.r.l.
Aferetica S.r.l. is an innovative startup in the biotechnology and healthcare industries, operating from Italy. Established in 2013, the company prides itself on its slogan: "Experience a groundbreaking fusion of knowledge and innovation to develop life-saving therapies and foster economic growth." Aferetica S.r.l.
Biomedical, Startup, Innovation, Therapy Development, Incubator, Economic Growth, Regional Recognition, National Recognition, Dialysis, Intensive Care, Cardiology, Medical Technologies, Job Creation, Industry Stimulus
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Aferetica S.r.l.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Aferetica S.r.l. on 13 Sep 2024. The 7 companies listed here were last checked between 11 Sep 2024 and 14 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.